{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Dose at which 100% of participants tolerated the dose","groups":[{"description":"Erlotinib\n\nerlotinib hydrochloride\n\npemetrexed disodium\n\nquality-of-life assessment\n\nintensity-modulated radiation therapy","id":"OG000","title":"Erlotinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"56 Days","title":"Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I)","type":"PRIMARY","unitOfMeasure":"mg"}